Xenothera

Executive Summary

Xenothera is a French biotechnology company leveraging its proprietary 'glyco-humanized' polyclonal antibody (GH-pAb) platform to develop novel immunotherapies for oncology, infectious diseases, and transplant-related conditions. Founded in 2014 and headquartered in Nantes, the company's platform aims to reduce immunogenicity and enhance therapeutic function compared to conventional polyclonal antibodies. Xenothera is at a preclinical to early clinical stage, with no disclosed pipeline specifics or financial details in public sources. The company's differentiated approach could address significant unmet needs, particularly in areas where polyclonal antibody therapies offer advantages over monoclonal antibodies, such as targeting multiple epitopes. However, as a private company with limited public information, the risk profile is elevated, and valuation remains unclear.

Upcoming Catalysts (preview)

• Q2 2027Phase 1/2 clinical data readout for lead oncology candidate35% success
• Q4 2026IND/CTA submission for infectious disease program50% success
• TBDStrategic partnership or licensing deal for transplant indication40% success